191 related articles for article (PubMed ID: 17450113)
1. Panitumumab (Vectibix) for metastatic colorectal cancer.
Med Lett Drugs Ther; 2007 Apr; 49(1259):35-6. PubMed ID: 17450113
[No Abstract] [Full Text] [Related]
2. Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer.
Burtness B
Oncology (Williston Park); 2007 Jul; 21(8):964-70; discussion 970, 974, 976-7. PubMed ID: 17715697
[TBL] [Abstract][Full Text] [Related]
3. The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective?
Lien K; Berry S; Ko YJ; Chan KK
Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):81-100. PubMed ID: 25400031
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
Jean GW; Shah SR
Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
[TBL] [Abstract][Full Text] [Related]
5. Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab.
You B; Chen EX
J Clin Pharmacol; 2012 Feb; 52(2):128-55. PubMed ID: 21427284
[TBL] [Abstract][Full Text] [Related]
6. Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report.
Heun J; Holen K
Clin Colorectal Cancer; 2007 May; 6(7):529-31. PubMed ID: 17553202
[TBL] [Abstract][Full Text] [Related]
7. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
Patel DK
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):31S-41S. PubMed ID: 18980550
[TBL] [Abstract][Full Text] [Related]
8. [Monoclonal antibodies therapies for colorectal cancer: cétuximab, panitumumab and bevacizumab].
Piront P; Van Daele D; Belaiche J; Polus M
Rev Med Liege; 2009; 64(5-6):274-8. PubMed ID: 19642458
[TBL] [Abstract][Full Text] [Related]
9. Panitumumab following disease progression on cetuximab in patients with metastatic colorectal cancer: a retrospective review.
Lau SC; Chung V; Lim D; Shibata S
J Oncol Pharm Pract; 2014 Apr; 20(2):83-7. PubMed ID: 23353714
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab: from biology to the care of colorectal cancer patients.
Vincenzi B; Santini D; Tonini G
Future Oncol; 2007 Oct; 3(5):497-9. PubMed ID: 17927513
[No Abstract] [Full Text] [Related]
11. Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer.
Saif MW; Syrigos KI; Hotchkiss S; Shanley J; Grasso J; Ferencz TM; Syrigos K; Shah MM
Cancer Chemother Pharmacol; 2009 Dec; 65(1):107-12. PubMed ID: 19415280
[TBL] [Abstract][Full Text] [Related]
12. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic.
Cohenuram M; Saif MW
Anticancer Drugs; 2007 Jan; 18(1):7-15. PubMed ID: 17159497
[TBL] [Abstract][Full Text] [Related]
13. Targeting the epidermal growth factor receptor in colorectal carcinoma.
Kurtin SE
Cancer Nurs; 2007; 30(4 Suppl 1):S1-9. PubMed ID: 17666985
[TBL] [Abstract][Full Text] [Related]
14. Role of panitumumab in the management of metastatic colorectal cancer.
Saif MW; Cohenuram M
Clin Colorectal Cancer; 2006 Jul; 6(2):118-24. PubMed ID: 16945167
[TBL] [Abstract][Full Text] [Related]
15. Introduction: Emerging therapies with epidermal growth factor receptor-targeted agents in colorectal cancer.
Chu E
Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S60-1. PubMed ID: 16336750
[No Abstract] [Full Text] [Related]
16. Where now for anti-EGF receptor therapies in colorectal cancer?
Shaw PH; Adams RA
Expert Rev Anticancer Ther; 2011 Oct; 11(10):1543-53. PubMed ID: 21999128
[TBL] [Abstract][Full Text] [Related]
17. Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature.
Saif MW; Peccerillo J; Potter V
Cancer Chemother Pharmacol; 2009 May; 63(6):1017-22. PubMed ID: 18781300
[TBL] [Abstract][Full Text] [Related]
18. [Panitumumab].
Musch A
Med Monatsschr Pharm; 2008 Apr; 31(4):122-6. PubMed ID: 18497243
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab vs EGFR antibodies in metastatic colorectal cancer.
Venook AP
Clin Adv Hematol Oncol; 2015 Feb; 13(2):90-2. PubMed ID: 25774477
[No Abstract] [Full Text] [Related]
20. Successful administration of panitumumab alone after severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer.
Cartwright TH; Genther R
Clin Colorectal Cancer; 2008 May; 7(3):202-3. PubMed ID: 18621639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]